StreetInsider.com News Articles

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Thu, 30 Jul 2026 08:31:00 -0400

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul

Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

GAITHERSBURG, Md., July 30, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, August 5,

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Thu, 30 Jul 2026 08:31:00 -0400

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul

Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Thu, 30 Jul 2026 08:31:00 -0400

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul

Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Thu, 30 Jul 2026 08:31:00 -0400

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul

Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs meets with East Asia partners to explore expansion

Mon, 27 Jul 2026 16:30:35 -0400

20/20 BioLabs, Inc. (Nasdaq: AIDX) announced that members of its management team attended the BIO Asia-Taiwan conference July 15-19 and held meetings in Taipei, Tokyo, and Seoul with companies, investors, laboratories, and potential commercial partners as part of what the company describes as an East Asia roll-up strategy.

The Gaithersburg, Maryland-based company said it is evaluating merger, acquisition, licensing, joint venture, and commercial partnership opportunities with East Asian companies whose products, customer relationships, data assets, laboratory infrastructure, or technology platforms may complement its blood-test business focused on early detection of cancers and chronic diseases.

According to a press release, the company is

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Mon, 27 Jul 2026 16:30:00 -0400

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region

Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases

GAITHERSBURG, Md., July 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that members of its management team participated in BIO Asia-Taiwan July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Mon, 27 Jul 2026 16:30:00 -0400

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region

Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Mon, 27 Jul 2026 16:30:00 -0400

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region

Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Mon, 27 Jul 2026 16:30:00 -0400

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region

Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases

20/20 BioLabs reaches standstill deal on Series E preferred stock

Thu, 23 Jul 2026 08:32:20 -0400

20/20 BioLabs, Inc. (Nasdaq: AIDX) announced it has entered into a standstill agreement with Streeterville Capital, LLC concerning the company's outstanding Series E Convertible Preferred Stock, effective July 16, 2026.

Under the agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into common stock for a 120-day period, unless the common stock trades at a price at least 10% above the "Minimum Price" as defined under Nasdaq Rule 5635 on a given trading day.

The standstill will terminate immediately if a breach of the agreement occurs or if an Event of Default, as defined in the Certificate

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Thu, 23 Jul 2026 08:31:00 -0400

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the “Agreement”) with Streeterville Capital, LLC (“Streeterville”) relating to the Company’s outstanding Series E Convertible Preferred Stock (the “Series E Preferred Stock”). The Agreement became effective on July 16, 2026.

Under the terms

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Thu, 23 Jul 2026 08:31:00 -0400

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

Under the terms

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Thu, 23 Jul 2026 08:31:00 -0400

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

Under the terms

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Thu, 23 Jul 2026 08:31:00 -0400

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution

Under the terms

Form 8-K 20/20 Biolabs, Inc. For: Jul 16

Wed, 22 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260722/26802355.html

Form 8-K 20/20 Biolabs, Inc. For: Jul 16

Wed, 22 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260722/26802355.html

20/20 BioLabs reports Q2 revenue growth, outlines Medicare strategy

Thu, 09 Jul 2026 16:01:42 -0400

20/20 BioLabs, Inc. (Nasdaq: AIDX) held an investor webinar on July 1, 2026, outlining its strategy for its OneTest™ for Cancer blood test, including a path toward potential Medicare reimbursement and preliminary second-quarter revenue figures.

The company said its second-quarter multi-cancer early detection revenue is expected to be its highest to date and at least 30% higher than the same period in 2025. The company noted these figures are preliminary and have not been reviewed by auditors.

The company described a federal statutory pathway, established by Congress, that allows Medicare reimbursement for FDA-authorized multi-cancer early detection tests beginning in 2028, subject to

20/20 BioLabs reports Q2 revenue growth, outlines Medicare strategy

Thu, 09 Jul 2026 16:01:42 -0400

The company described a federal statutory pathway, established by Congress, that allows Medicare reimbursement for FDA-authorized multi-cancer early detection tests beginning in 2028, subject to

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Thu, 09 Jul 2026 16:01:00 -0400

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection

GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today highlighted key themes from its inaugural investor webinar held on July 1, 2026. The Company presented its strategy for advancing OneTest™ for Cancer toward potential Medicare reimbursement under the new statutory pathway for FDA-authorized multi-cancer early detection

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Thu, 09 Jul 2026 16:01:00 -0400

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Thu, 09 Jul 2026 16:01:00 -0400

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Thu, 09 Jul 2026 16:01:00 -0400

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection

Form 8-K 20/20 Biolabs, Inc. For: Jul 01

Wed, 01 Jul 2026 15:29:00 -0400

si-local-file:///var/storage/secattach/20260701/26720190.html

Form DEFA14A 20/20 Biolabs, Inc.

Tue, 23 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26680414.html

Form DEF 14A 20/20 Biolabs, Inc. For: Aug 18

Tue, 23 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260623/26680406.html